Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Università Cattolica del Sacro Cuore, Rome, Italy.
Lung. 2020 Jun;198(3):429-440. doi: 10.1007/s00408-020-00360-3. Epub 2020 May 15.
Fibrotic hypersensitivity pneumonitis is a complex interstitial lung disease that is not entirely understood. In its chronic and fibrotic form, hypersensitivity pneumonitis is one of the main mimickers of idiopathic pulmonary fibrosis (IPF). Distinguishing between these two conditions is challenging but is of particular clinical relevance. Two approved therapies are available for IPF, and a considerable number of clinical trials are now exploring newer pharmacological options. This impressive research effort is a consequence of new pathogenetic understanding, updated diagnostic criteria and a long history of pharmacological trials. Conversely, current knowledge gaps on pathogenesis of chronic hypersensitivity pneumonitis, coupled with lack of validated diagnostic criteria, make the management of this disease an unsolved clinical challenge. This also reflects the paucity of therapeutic clinical trials in this field. In this review, we describe the current evidence and the possible future options to approach this complex disease.
纤维化性过敏性肺炎是一种复杂的间质性肺疾病,目前尚未完全了解。在慢性和纤维化形式中,过敏性肺炎是特发性肺纤维化(IPF)的主要模拟疾病之一。区分这两种情况具有挑战性,但具有特殊的临床意义。目前有两种批准用于 IPF 的治疗方法,现在有相当数量的临床试验正在探索新的药物治疗选择。这种令人印象深刻的研究工作是新发病理机制理解、更新的诊断标准和长期药物试验的结果。相反,慢性过敏性肺炎发病机制的现有知识空白,加上缺乏经过验证的诊断标准,使得这种疾病的治疗成为一个悬而未决的临床挑战。这也反映了该领域治疗性临床试验的缺乏。在这篇综述中,我们描述了目前的证据和可能的未来选择来处理这种复杂的疾病。